Novadaq Technologies Inc.  

(Public, NASDAQ:NVDQ)   Watch this stock  
Find more results for NVDQ
+0.17 (1.43%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.96 - 12.40
52 week 9.40 - 18.24
Open 11.96
Vol / Avg. 210,274.00/378,283.00
Mkt cap 669.89M
P/E     -
Div/yield     -
EPS -0.74
Shares 56.20M
Beta 0.99
Inst. own     -
Feb 22, 2016
Q4 2015 Novadaq Technologies Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2015
Novadaq Technologies Inc at Piper Jaffray Healthcare Conference - 12:30PM EST - Add to calendar
Nov 19, 2015
Novadaq Technologies Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 18, 2015
Novadaq Technologies Inc at Stifel Healthcare Conference
Nov 16, 2015
Novadaq Technologies Inc Analyst & Investor Day
Oct 28, 2015
Q3 2015 Novadaq Technologies Inc Earnings Call
Oct 28, 2015
Q3 2015 Novadaq Technologies Inc Earnings Release
Sep 17, 2015
Novadaq Technologies Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    


5090 Explorer Dr Suite 202
+1-905-6293822 (Phone)
+1-905-6290282 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables, capital devices or consumable products, the rental of capital devices, royalties, upfront payments received from partners for exclusive sales and marketing rights, and extended warranty services agreements in connection with capital sales. The Company’s SPY imaging products are SPY Elite, FIREFLY, LUNA, PINPOINT, CO2 HEART LASER systems and DermACELL Advanced Decellularized Dermis. The SPY Imaging System is United States Food and Drug Administration (FDA) cleared for use in seven surgical specialties, including coronary artery bypass, cardiovascular, plastic, reconstructive, micro, organ transplant and gastrointestinal surgery.

Officers and directors

Arun Menawat Ph.D. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Roger Deck Chief Financial Officer
Bio & Compensation  - Reuters
Anthony F. Griffiths Independent Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Patrice E. Merrin Director
Age: 66
Bio & Compensation  - Reuters
Robert S. White Director
Bio & Compensation  - Reuters
Aaron Davidson Independent Director
Age: 46
Bio & Compensation  - Reuters
Harold O. Koch Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters